Browse studies, page 1304
Page 1304 of 1,318, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis Microbial pathogenesis, 2022
- A comparison of different antibiotic regimens for the treatment of infective endocarditis The Cochrane database of systematic reviews, 2020
- Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review Helicobacter, 2024
- Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis Wiener klinische Wochenschrift, 2010
- Treatment of community-acquired pneumonia with levofloxacin: 500 mg once a day or 500 mg twice a day? Presse medicale (Paris, France : 1983), 2000
- A comparison of different antibiotic regimens for the treatment of infective endocarditis The Cochrane database of systematic reviews, 2016
- Levofloxacin adverse effects, data from clinical trials and pharmacovigilance Therapie, 2001
- Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis Medicine, 2020
- Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line World journal of gastroenterology, 2012
- Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis Drugs, 2017
- Antimicrobial therapy for chronic bacterial prostatitis The Cochrane database of systematic reviews, 2013
- Primary antibiotic resistance in Helicobacter pylori in China: a systematic review and meta-analysis Journal of global antimicrobial resistance, 2023
- Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis The Journal of antimicrobial chemotherapy, 2010
- Fluoroquinolones for treating tuberculosis (presumed drug-sensitive) The Cochrane database of systematic reviews, 2013
- Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients European Respiratory Journal, 2019
- Application of fluoroquinolone pharmacodynamics Journal of Antimicrobial Chemotherapy, 2000
- Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model Journal of Antimicrobial Chemotherapy, 2006
- Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae The American Journal of Medicine, 2001
- Pharmacodynamic Analysis of Ceftriaxone, Gatifloxacin, and Levofloxacin Against Streptococcus pneumoniae with the Use of Monte Carlo Simulation Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, 2005
- ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model Journal of Antimicrobial Chemotherapy, 2004
- Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae : Report from the Antimicrobial Resistance Rate Epidemiology Study Team Antimicrobial Agents and Chemotherapy, 2002
- Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects Antimicrobial Agents and Chemotherapy, 2004
- Mutant Prevention Concentration-Based Pharmacokinetic/Pharmacodynamic Indices as Dosing Targets for Suppressing the Enrichment of Levofloxacin-Resistant Subpopulations of Staphylococcus aureus Antimicrobial Agents and Chemotherapy, 2011
- Pharmacodynamics of Trovafloxacin and Levofloxacin against Bacteroides fragilis in an In Vitro Pharmacodynamic Model Antimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae Diagnostic Microbiology and Infectious Disease, 2002
- Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy? Antimicrobial Agents and Chemotherapy, 2006
- Pharmacodynamic Modeling of the Evolution of Levofloxacin Resistance in Staphylococcus aureus Antimicrobial Agents and Chemotherapy, 2005
- Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus Journal of Antimicrobial Chemotherapy, 2008
- Pharmacodynamically Guided Levofloxacin Dosing for Pediatric Community-Acquired Pneumonia Journal of the Pediatric Infectious Diseases Society, 2016
- Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy, 2001
- Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy, 1999
- Pharmacokinetics and Pharmacodynamics of Levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in Human Skin Blister Fluid Antimicrobial Agents and Chemotherapy, 2000
- Evaluation of Efficacy and Safety Parameters of Different Antibiotics Regimens for Management of Empyema ClinicalTrials.gov · COMPLETED, 2026
- Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis ClinicalTrials.gov · COMPLETED, 2007
- A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder ClinicalTrials.gov · TERMINATED, 2013
- Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP) ClinicalTrials.gov · COMPLETED, 2015
- Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB ClinicalTrials.gov · COMPLETED, 2022
- Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin ClinicalTrials.gov · COMPLETED, 2014
- Urinary Bactericidal Activity of 4 Doses of Levofloxacin (250, 500, &750, and 1000 mg) Against Fluoroquinolone-Resistant E. Coli ClinicalTrials.gov · COMPLETED, 2006
- Comparison between the antimicrobial activity of colistin and ceftazidime-avibactam against multidrug-resistant Pseudomonas aeruginosa isolated from patients with ventilator-associated pneumonia in intensive care units of Kasr Al-Ainy hospitals BMC infectious diseases, 2026
- Effects of acute renal failure and ganciclovir on the pharmacodynamics of levofloxacin-induced seizures in rats Biological & pharmaceutical bulletin, 2007
- The pharmacokinetics (PK) / pharmacodynamics (PD) of pretomanid, delamanid and bedaquiline in the BALB/c mouse model of central nervous system tuberculosis BMC infectious diseases, 2026
- Genomic phylogeny, taxonomic classification, genetic landscape, and antibiotic resistance of clinical Stenotrophomonas isolates Frontiers in microbiology, 2026
- Cefiderocol in Children with Hematologic Malignancies-The Multicenter Retrospective Experience of the Infection Working Group of the Italian Pediatric Hematology and Oncology Association (AIEOP) Journal of clinical medicine, 2026
- Evaluation of lung epithelial lining fluid concentrations of lascufloxacin against Streptococcus pneumoniae in a hollow-fiber infection model The Journal of antibiotics, 2025
- An Antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents in the Philippines against Enterobacterales and Pseudomonas aeruginosa from different infection sites: results from ATLAS surveillance program (2018-2021) BMC infectious diseases, 2026
- Managing Infections in Burn Patients: Strategies and Considerations for Antimicrobial Dosing European burn journal, 2025
- Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients Clinical pharmacokinetics, 2005
- Anti-Shigella activity and killing kinetics of compounds from MMV Pathogen and COVID Boxes: Identifying leads against Shigellosis Current research in pharmacology and drug discovery, 2026
- Evaluation of Antibiotic Use in Patients Admitted to a Hungarian Intensive Care Unit with Pneumonia and Sepsis: Retrospective Observational Before-After Study Antibiotics (Basel, Switzerland), 2026
- Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis Chest, 2005
- Association between antimicrobial regimens and 28-day mortality in patients with Stenotrophomonas maltophilia infection: a propensity score-weighted analysis Microbiology spectrum, 2026
- Trip score - A three-pillar risk stratification model proposal for antibiotic and immunomodulator coadministration Frontiers in pharmacology, 2026
- Efflux pump overexpression in fluoroquinolone multidrug resistance: molecular mechanisms, PK/PD implications, global epidemiology, and translational strategies Frontiers in pharmacology, 2026
- Recurrence of Postneurosurgical Central Nervous System Infection Caused by Acinetobacter baumannii in a Critically Ill Patient Treated With Cefiderocol. A Case Report Case reports in infectious diseases, 2026
- Antimicrobial and Synergistic Activity of Metformin Against Helicobacter pylori The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026
- ESKAPE pathogens: Emerging isolates in odontogenic orofacial infections Journal of oral biology and craniofacial research, 2026
- Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae Postgraduate medicine, 2008
- Understanding the Role of Macrocycle Size and Amide Linkage in Teixobactin Analogues Biomolecules, 2026
- A Study of Antibiotic Tolerance to Levofloxacin and Rifampin in Staphylococcus aureus Isolates Causing Prosthetic Joint Infections: Clinical Relevance and Treatment Challenges Antibiotics (Basel, Switzerland), 2025
- Do Aminopenicillins Have a Role in Treating Ampicillin-Resistant Enterococcus UTIs? Open forum infectious diseases, 2025
- The Potential Role of Verapamil Against Fluconazole-Induced Torsade de Pointes: A Critical Review Health science reports, 2026
- In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against Streptococcus pneumoniae Responsible for Lower Respiratory Tract Infections in the United States (2016-2020), Including Resistant Subsets and Select Serotypes Antibiotics (Basel, Switzerland), 2026
- Prevalence of polypharmacy and drug interactions in geriatric patients: A cross-sectional study from India PloS one, 2026
- Hemodialysis Central Venous Catheter-Associated Bloodstream Infection Caused by Stenotrophomonas maltophilia Treated with Cefiderocol and Levofloxacin After Failure of Trimethoprim-Sulfamethoxazole Monotherapy and Device Replacement Antibiotics (Basel, Switzerland), 2026
- Antibacterial therapy in central nervous system infections - breakpoints versus minimal inhibitory concentrations related to body fluid levels Infection, 2026
- Wild-type MIC distribution and evaluation of epidemiological cut-offs of second-line TB-drugs in susceptible and MDR-TB clinical isolates from Chennai, India Frontiers in microbiology, 2026
- Population pharmacokinetics and exposure-response analysis of levofloxacin in Chinese pediatric patients with severe refractory Mycoplasma pneumoniae pneumonia Antimicrobial agents and chemotherapy, 2026
- Effect of Quinolone Prophylaxis Discontinuation During Pre-engraftment Neutropenia on Incidence, Mortality, and Etiology of Bloodstream Infections in Hematopoietic Stem-cell Transplant Recipients: A Systematic Review and Meta-analysis Open forum infectious diseases, 2026
- Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms Antimicrobial agents and chemotherapy, 2026
- Targeted Prostatic Delivery of Levofloxacin via a Novel Vas-Deferens Injection Device: A Pharmacokinetic Study in Rats Pharmaceutics, 2026
- Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy C hinese volunteers and dosing regimen optimization Journal of clinical pharmacy and therapeutics, 2013
- Determinants of levofloxacin prophylaxis failure in high-risk haematology patients: a prospective study integrating resistant colonization and pharmacokinetic/pharmacodynamic target attainment The Journal of antimicrobial chemotherapy, 2026
- Characterization of gepotidacin activity, including in vitro kill kinetics, checkerboard, and PAE/SME testing against gram-positive and gram-negative bacteria Microbiology spectrum, 2026
- A Ten-Year Trend of Antimicrobial Resistance in Pseudomonas aeruginosa From United States Medical Centers: Results From the INFORM Surveillance Program (2015-2024) Open forum infectious diseases, 2026
- Three fluoroquinolones with different epithelial lining fluid penetration in a murine lung infection model: an experimental site-specific PK/PD study Antimicrobial agents and chemotherapy, 2026
- Nemonoxacin pharmacokinetics/pharmacodynamics against Escherichia coli in an in vitro dynamic urinary tract infection model Antimicrobial agents and chemotherapy, 2026
- Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation Experimental and therapeutic medicine, 2020
- Differential Antimicrobial Susceptibilities of Granulicatella adiacens and Abiotrophia defectiva Antimicrobial agents and chemotherapy, 2016
- Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis Expert review of respiratory medicine, 2015
- Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections The Journal of antimicrobial chemotherapy, 2022
- Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae Antimicrobial agents and chemotherapy, 2004
- Culture-Based Antimicrobial Susceptibility Testing for Helicobacter pylori Methods in molecular biology (Clifton, N.J.), 2021
- Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones Pediatric pulmonology, 2013
- Fluoroquinolones in the management of community-acquired pneumonia in primary care Expert review of anti-infective therapy, 2010
- In vivo pharmacodynamics of lascufloxacin and levofloxacin against Streptococcus pneumoniae and Prevotella intermedia in a pneumonia mixed-infection mouse model Anaerobe, 2021
- Antibiotic Dosing in Continuous Renal Replacement Therapy Advances in chronic kidney disease, 2017
- Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects International journal of antimicrobial agents, 2006
- Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations Infection, 2005
- Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function Antimicrobial agents and chemotherapy, 2017
- Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018
- Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients Antimicrobial agents and chemotherapy, 2017
- Probability of target attainment of oral antimicrobials for Escherichia coli and Klebsiella pneumoniae based on Monte Carlo simulations Diagnostic microbiology and infectious disease, 2022
- Mechanochemically Induced Solid-State Transformations of Levofloxacin Molecular pharmaceutics, 2024
- Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia International journal of antimicrobial agents, 2007
- The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019 Drugs, 2019
- Design, synthesis, spectroscopic characterization, in-vitro antibacterial evaluation and in-silico analysis of polycaprolactone containing chitosan-quercetin microspheres Journal of Biomolecular Structure and Dynamics, 2022
- Mutation of smeRv Renders Stenotrophomonas maltophilia Resistant to First-Line Antibiotics Trimethoprim/Sulfamethoxazole and Levofloxacin Antibiotics, 2025
- Importance of Gastric Secretion and the Rapid Gastric Emptying of Ingested Water along the Lesser Curvature ("Magenstraße") in Predicting the In Vivo Performance of Liquid Oral Dosage Forms in the Fed State Using a Modeling and Simulation Molecular Pharmaceutics, 2022
- Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences Genome Medicine, 2015
